Pesquisar
Valneva SE
VALNAdicionar à lista de desejos
5.225USD
+0.135+2.65%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
453.93MValor de mercado
PerdaP/L TTM
Mais detalhes de Valneva SE Empresa
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Informações de Valneva SE
Código da empresaVALN
Nome da EmpresaValneva SE
Data de listagemJun 28, 2007
CEOLingelbach (Thomas)
Número de funcionários- -
Tipo de títulosDepository Receipt
Fim do ano fiscalJun 28
Endereço6, Rue Alain Bombard
CidadeSAINT-HERBLAIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísFrance
Código postal44800
Telefone33228073710
Sitehttps://valneva.com/
Código da empresaVALN
Data de listagemJun 28, 2007
CEOLingelbach (Thomas)
Executivos da empresa Valneva SE
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Peter Buehler
Mr. Peter Buehler
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. James Connolly
Mr. James Connolly
Independent Director
Independent Director
--
--
Ms. Mailys Ferrere
Ms. Mailys Ferrere
Director, Representative of Bpifrance Participations SA
Director, Representative of Bpifrance Participations SA
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Valneva SE?
Os cinco principais acionistas de Valneva SE são: Mr. Franck Grimaud
Quantas instituições possuem ações da Valneva SE (VALN)?
Em 2026Q1, 36 instituições possuíam ações da Valneva SE, com valor de mercado aproximado de 5.21M, representando 5.50% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -309162.00.
Qual é a maior fonte de receita da Valneva SE?
Em 2026Q1, o segmento de negócios IXIARO gerou a maior receita para Valneva SE, totalizando 98.42M e representando 56.35% da receita total.